Related Experiment Video
Updated: Jun 26, 2026
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Jawing about TNF: new hope for cherubism
Deborah Veis Novack1, Roberta Faccio
1Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. novack@wustl.edu
Cell
|January 16, 2007
Summary
Mutations in SH3-domain binding protein 2 (SH3BP2) cause cherubism, a rare childhood disorder. This study reveals that SH3BP2 mutations enhance myeloid cell production of TNF-alpha, leading to jaw inflammation and bone loss.
Area of Science:
- Genetics and Molecular Biology
- Immunology
- Developmental Biology
Background:
- Cherubism is a rare pediatric disorder linked to SH3BP2 mutations, causing jaw inflammation and bone loss.
- The precise molecular mechanisms underlying cherubism pathogenesis have remained largely undetermined.
- Understanding SH3BP2's role is crucial for elucidating cherubism's complex etiology.
Discussion:
- This research elucidates a key mechanism in cherubism by linking SH3BP2 mutations to increased TNF-alpha production.
- Activated SH3BP2 in myeloid cells drives inflammatory responses and subsequent bone resorption in the jaw.
- The findings highlight the critical interplay between genetic mutations, immune cell function, and skeletal pathology.
Key Insights:
- Cherubism-associated SH3BP2 mutations activate the protein, leading to heightened pro-inflammatory cytokine TNF-alpha production.
- Myeloid-derived TNF-alpha is identified as a central mediator of both inflammation and bone loss in a mouse model.
- This study provides a direct mechanistic link between SH3BP2 dysfunction and the characteristic symptoms of cherubism.
Outlook:
- Further research can explore targeted therapies aimed at inhibiting TNF-alpha or modulating SH3BP2 activity.
- Investigating SH3BP2's upstream regulators and downstream effectors could reveal additional therapeutic targets.
- This work paves the way for improved diagnostic and therapeutic strategies for cherubism patients.
More Related Videos
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
02:26NF-kB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...